Compare CRNX & COLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | COLD |
|---|---|---|
| Founded | 2008 | 1903 |
| Country | United States | United States |
| Employees | N/A | 12690 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.3B |
| IPO Year | 2018 | 2009 |
| Metric | CRNX | COLD |
|---|---|---|
| Price | $33.97 | $14.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 16 |
| Target Price | ★ $76.75 | $14.97 |
| AVG Volume (30 Days) | 1.2M | ★ 4.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 7.67% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,039,000.00 | ★ $2,601,846,000.00 |
| Revenue This Year | $720.10 | N/A |
| Revenue Next Year | $184.67 | $2.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $10.10 |
| 52 Week High | $57.99 | $18.08 |
| Indicator | CRNX | COLD |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 57.09 |
| Support Level | $33.36 | $11.93 |
| Resistance Level | $37.23 | $15.38 |
| Average True Range (ATR) | 1.36 | 0.45 |
| MACD | -0.23 | -0.09 |
| Stochastic Oscillator | 29.09 | 49.77 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Americold Realty Trust Inc is the world's second-largest owner and operator of temperature-controlled warehouses behind privately held Lineage Logistics. The Atlanta, Georgia-based firm owns and operates approximately 231 temperature-controlled warehouses, spanning 1.4 billion cubic feet. In 2022, the firm derived more than 80% of its revenue from the United States but also has sizable operations in Europe, Canada, Australia, and New Zealand. Americold supplements its core business by providing supply management and transportation services to its various customers. It operates as a real estate investment trust.